When is digoxin considered in CHF management?

When is digoxin considered in CHF management?

• A. In symptomatic HFrEF despite GDMT, especially with concurrent atrial fibrillation; may reduce hospitalizations
• B. First-line therapy for all HF
• C. Only in HF with preserved EF
• D. Not used in heart failure

Answer: (A)

Digoxin is best used as an added, symptom-relief option in heart failure with reduced ejection fraction (HFrEF) when patients remain symptomatic despite guideline-directed medical therapy. It is particularly useful in patients who also have atrial fibrillation or flutter, where its ability to slow the heart rate via increased vagal tone can improve symptoms and rhythm control. The important practical point is that digoxin has not been shown to reduce mortality, but it can reduce heart failure hospitalizations, making it a valuable adjunct rather than a first-line mortality-reducing therapy. A few key context notes help solidify why this is the right use: standard HFrEF treatment (GDMT) includes ACE inhibitors or ARNI, beta-blockers, mineralocorticoid receptor antagonists, and newer agents like SGLT2 inhibitors. Digoxin fits in after GDMT when symptoms persist. It is not typically used in heart failure with preserved ejection fraction, and it should not be considered a universal, first-line treatment for all heart failure. It also requires careful dosing and monitoring due to a narrow therapeutic window and potential toxicity, especially in kidney impairment or with interacting drugs. So the best choice is adding digoxin in symptomatic HFrEF despite GDMT, with particular benefit in patients who have atrial fibrillation, as it can reduce hospitalizations by improving symptoms and rate control.

Digoxin is best used as an added, symptom-relief option in heart failure with reduced ejection fraction (HFrEF) when patients remain symptomatic despite guideline-directed medical therapy. It is particularly useful in patients who also have atrial fibrillation or flutter, where its ability to slow the heart rate via increased vagal tone can improve symptoms and rhythm control. The important practical point is that digoxin has not been shown to reduce mortality, but it can reduce heart failure hospitalizations, making it a valuable adjunct rather than a first-line mortality-reducing therapy.

A few key context notes help solidify why this is the right use: standard HFrEF treatment (GDMT) includes ACE inhibitors or ARNI, beta-blockers, mineralocorticoid receptor antagonists, and newer agents like SGLT2 inhibitors. Digoxin fits in after GDMT when symptoms persist. It is not typically used in heart failure with preserved ejection fraction, and it should not be considered a universal, first-line treatment for all heart failure. It also requires careful dosing and monitoring due to a narrow therapeutic window and potential toxicity, especially in kidney impairment or with interacting drugs.

So the best choice is adding digoxin in symptomatic HFrEF despite GDMT, with particular benefit in patients who have atrial fibrillation, as it can reduce hospitalizations by improving symptoms and rate control.